EcoDrugPlus

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSBSLG00000004962
Gene Symbol: LOC114845208
3 Cross references
202 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSBSLG00000002510
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSBSLG00000007382
Gene Symbol: LOC114867698
2 Cross references
195 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSBSLG00000004810
Gene Symbol: EGLN1
3 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSBSLG00000007597
Gene Symbol: EGLN3
3 Cross references
200 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSBSLG00000024044
Gene Symbol: LOC114870735
3 Cross references
211 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSBSLG00000021644
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSBSLG00000007112
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSBSLG00000017822
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSBSLG00000022367
Gene Symbol: EDNRB
3 Cross references
200 Possible Orthologues:

Endothelin-1 Receptor-Like

Ensembl ID : ENSBSLG00000001022
Gene Symbol: LOC114868681
3 Cross references
200 Possible Orthologues:

Endothelin-1 Receptor-Like

Ensembl ID : ENSBSLG00000000783
Gene Symbol: LOC114868689
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).